Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Inclusion Criteria: Histologically confirmed solid tumor or lymphomas (Accrual for Lymphoma Patients Closed as of 11/27/09) Refractory to standard treatment OR no standard treatment that is potentially curative or capable of prolonging life expectancy exists Tumor amenable to biopsy (patients accrued at the MTD only) No CNS metastases Performance status - ECOG 0-2 At least 12 weeks Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Bilirubin ≤ 2 times upper limit of normal (ULN) AST ≤ 2.5 times ULN Alkaline phosphatase ≤ 2 times ULN (5 times ULN if due to liver involvement) Creatinine ≤ 2 times ULN QTc < 500 msec for men (470 msec for women) LVEF > 40% by echocardiogram Ejection fraction normal by echocardiogram (for patients who have received prior anthracycline therapy) No cardiac symptoms ≥ grade 2 No New York Heart Association class III or IV heart failure No myocardial infarction within the past year No active ischemic heart disease within the past year No congenital long QT syndrome No left bundle branch block No history of uncontrolled dysrhythmias or requiring antiarrhythmic drugs No history of cardiac toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine) No poorly controlled angina No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row) No other significant cardiac disease Pulse oximetry at rest and exercise < 88% (per Medicare guidelines) No pulmonary symptoms ≥ grade 2 No significant pulmonary disease requiring oxygen supplementation or causing a severe limitation in activity No symptomatic pulmonary disease requiring medication including any of the following: Dyspnea on or off exertion Paroxysmal nocturnal dyspnea Oxygen requirement and significant pulmonary disease, including chronic obstructive/restrictive pulmonary disease No home oxygen use that meets the Medicare criteria No history of pulmonary toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine) No seizure disorder No sensory peripheral neuropathy > grade 1 No neuropathic pain of any etiology Patients with residual peripheral neuropathy ≤ grade 1 due to oxaliplatin therapy allowed No uncontrolled infection No prior serious allergic reaction to eggs Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Willing to return to Mayo Clinic Rochester, Mayo Clinic Arizona, or Mayo Clinic Florida for follow up More than 4 weeks since prior immunotherapy or biologic therapy No concurrent prophylactic colony-stimulating factors No concurrent immunotherapy, biologic therapy, or gene therapy More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) No other concurrent chemotherapy Concurrent steroids (at a stable dose for ≥ 4 weeks) for comorbid conditions (e.g., adrenal insufficiency or rheumatoid arthritis) allowed More than 4 weeks since prior radiotherapy No prior radiotherapy that potentially included the heart in the field (e.g., mantle) or chest No prior radiotherapy to > 25% of bone marrow No prior radiopharmaceuticals No concurrent radiotherapy Recovered from prior therapy More than 8 weeks since prior UCN-01 No concurrent warfarin Low molecular weight heparin allowed No concurrent medications that prolong or may prolong QTc interval No other concurrent investigational therapy